Bristol Myers Squibb (CELG-RI) Goodwill & Intangibles (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Goodwill & Intangibles of $39.1 billion for Q2 2026, down 9.33% year-over-year from $43.2 billion in Q2 2025, and down 2.14% quarter-over-quarter from $40.0 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Goodwill & Intangibles for 18 consecutive years, with $39.1 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Goodwill & Intangibles fell 9.33% year-over-year to $39.1 billion; the TTM figure through Jun 2026 stood at $39.1 billion (down 9.33% YoY), while the FY2025 annual figure was $40.9 billion, down 9.26% from the prior year.
- Goodwill & Intangibles eased to $39.1 billion in Q2 2026 per CELG-RI's latest filing, from $40.0 billion in the prior quarter.
- Across five years, Goodwill & Intangibles topped out at $60.6 billion in Q1 2022 and bottomed at $39.1 billion in Q2 2026.
- Historically, Goodwill & Intangibles has averaged $49.4 billion across 5 years, with a median of $49.4 billion in 2023.
- Annual changes were most pronounced in 2024 — Goodwill & Intangibles retreated 0.43% — and 2025, when it fell 18.85%.
- Bristol Myers Squibb's Goodwill & Intangibles stood at $57.0 billion in 2022, then decreased by 15.38% to $48.2 billion in 2023, then dropped by 6.66% to $45.0 billion in 2024, then dropped by 9.26% to $40.9 billion in 2025, then fell by 4.23% to $39.1 billion in 2026.
- Business Quant data shows CELG-RI's Goodwill & Intangibles at $39.1 billion in Q2 2026, $40.0 billion in Q1 2026, and $40.9 billion in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.13 Bn |
| Mar 31, 2026 | 39.98 Bn |
| Dec 31, 2025 | 40.86 Bn |
| Sep 30, 2025 | 42.21 Bn |
| Jun 30, 2025 | 43.15 Bn |
| Mar 31, 2025 | 44.22 Bn |
| Dec 31, 2024 | 45.03 Bn |
| Sep 30, 2024 | 48.72 Bn |
| Jun 30, 2024 | 51.16 Bn |
| Mar 31, 2024 | 54.50 Bn |
| Dec 31, 2023 | 48.24 Bn |
| Sep 30, 2023 | 50.10 Bn |
| Jun 30, 2023 | 52.47 Bn |
| Mar 31, 2023 | 54.73 Bn |
| Dec 31, 2022 | 57.01 Bn |
| Sep 30, 2022 | 59.29 Bn |
| Jun 30, 2022 | 58.14 Bn |
| Mar 31, 2022 | 60.60 Bn |
| Dec 31, 2021 | 63.03 Bn |
| Sep 30, 2021 | 65.45 Bn |